GH Research (GHRS) announced the commencement of an underwritten public offering of $150M of ordinary shares. All of the ordinary shares are to be offered by GH Research. Cantor, Stifel and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity and Citizens JMP are acting as co-lead managers for the offering.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GHRS:
- GH Research’s GH001 Shows Promising Results in TRD Phase 2b Trial
- GH Research announces primary endpoint met in Phase 2b trial of GH001
- GH Research to Update on Promising TRD Treatment Trial
- GH Research Achieves Key Milestones in Depression Trials and Prepares FDA Response
- GH Research sees top-line data from Phase 2b trial in TRD in Q1